C

Cellectis SA

D
CLLS
USD
0.04
(1.7544%)
Market Closed
492.00
Volume
-0.95091
EPS
-
Div Yield
-1.893364
P/E
232,217,233.20
Market Cap
Today
1.7544%
1 Week
-3.333%
1 Month
8.920%
6 Months
-3.734%
12 Months
41.463%
Year To Date
-23.684%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
B
BLUE
-0.0046
(-0.9287%)
USD
C
CRSP
-0.11
(-0.2219%)
USD
E
EDIT
0.05
(1.292%)
USD
N
NTLA
0.41
(1.8214%)
USD
S
SGMO
0.0617
(7.3584%)
USD
VRTX
VRTX
3.93
(0.8292%)
USD
A
ALNY
3.06
(1.1203%)
USD
GILD
GILD
0.015
(0.0179%)
USD
B
BMRN
0.31
(0.4359%)
USD

Title:
Cellectis SA

Sector:
Healthcare
Industry:
Biotechnology
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.
Do you need help or have a question?
Contact Us